Applications of Mixed Effects Modeling
Tuesday 3 June, 2:40--4:30

Organizer: Jose' PINHEIRO
Bell Labs
Moderator: Chuanhai LIU
Bell Labs

Analyzing Data with Multiple Levels of Nesting Using Mixed-Effects Models

Jos\'e C. PINHEIRO
Lucent Technologies, Murray Hill, NJ, USA
Douglas M. BATES
University of Wisconsin, Madison, WI, USA
Grouped data can be loosely defined as data in which the observations are classified into disjoint groups. Some examples are data from longitudinal studies or from split-plot designs. Observations in the same group are usually correlated and mixed-effects models constitute a powerful tool for modeling this within-group dependence. Although grouped data with a single grouping factor are the rule in Biology and Medicine, data with multiple nested classification factors are frequently collected in industrial experiments and in sociological studies. Displaying and fitting mixed-effects models to multiple-nested data is considerably more challenging than for grouped data with a single grouping factor. We describe extensions to our \textsf{nlme} library for \textsf{S-PLUS} to handle data with multiple levels of nesting. These include different classes of data structures, graphical displays based on the \textsf{trellis} library, and efficient algorithms for maximum likelihood estimation. A real example from integrated circuits manufacturing is used to illustrate the proposed methods.

[Jos\'e C. Pinheiro, Bell Labs, Lucent Technologies, 600 Mountain Avenue Rm 2C-258, Murray Hill, NJ 07974-2070, USA, jcp@bell-labs.com]


Using Pharmacokinetic and Pharmacodynamic Modeling to Guide Dose Selection in Drug Development : A Case Study

David M. GILTINAN
Genentech Inc., San Francisco, CA, USA
Determining an appropriate dosing regimen for a new drug in clinical development is usually guided by the idea of a ``therapeutic window'' for circulating drug concentration. The aim of dosing is to maintain the drug concentration in the bloodstream within a target range; concentrations which are too low may be subtherapeutic, while exceeding the upper limit of the range may lead to toxicity. Maintaining drug levels within the desired limits may be complicated by large inter-subject variability in both the pharmacokinetic and the pharmacodynamic response to the drug. The former can result in large disparities in circulating drug levels in two subjects following the same dosage regimen, while the latter corresponds to differences in the concentration-effect relationship, so that a common target range may not be appropriate for all subjects. Accurate characterization of inter-subject variation in pharmacokinetics and pharmacodynamics is thus essential to determine an appropriate dosing strategy. Typically, such characterization must be accomplished on the basis of infrequent, irregularly spaced, measurements of pharmacokinetic and pharmacodynamic response in subjects receiving the drug, though the number of subjects may be large. The nonlinear mixed effects model provides a useful framework for analyzing repeated measurement data of this type. Methods for inference in this model framework will be discussed and their application to investigating dosing strategies will be illustrated using data from a clinical study of a novel cardiovascular agent.

[David M. Giltinan, Genentech Inc., San Francisco, CA, USA, giltinan@gene.com]


Back to JRC program
Back to JRC Home Page